For decades, paper Case Report Forms (CRFs) were the standard method for collecting clinical trial data. Investigators filled out physical forms by hand, shipped them to data management centers, and waited for double data entry teams to transcribe the information into electronic databases. It worked, but it was slow, expensive, and error-prone.
Today, Electronic Data Capture (EDC) systems have largely replaced paper CRFs across the clinical trial industry. With EDC adoption now exceeding 70% across all trial phases and reaching approximately 90% in Phase I studies, the transition from paper to digital is well advanced. Yet some organizations — particularly smaller medical device companies, academic institutions, and certain regional trial programs — still rely on paper-based processes.
This article provides a detailed comparison of EDC systems and paper CRFs, examining how they differ across every dimension that matters: data quality, cost, speed, regulatory compliance, and long-term scalability. For a broader view of how EDC systems work in clinical trials, our pillar article covers the underlying technology in depth.
What Are Paper CRFs?
A paper Case Report Form is a printed document designed to capture specific data points defined by the clinical trial protocol. At each study visit, investigators and site staff fill in the form by hand, recording patient demographics, medical history, vital signs, adverse events, laboratory results, and other protocol-required information.
Once completed, paper CRFs follow a multi-step process before data becomes available for analysis. The original or a copy is shipped physically to a central data management facility, where trained personnel manually transcribe the handwritten data into a clinical database. To minimize transcription errors, most organizations perform double data entry, where two individuals enter the same data independently and discrepancies are flagged for resolution.
Query management follows a similarly manual path via Data Clarification Forms (DCFs). When issues are identified — missing values, illegible entries, out-of-range results — a DCF is sent back to the site, the investigator responds, and the database is updated accordingly. As published research has documented, this process is laborious and time-consuming, directly impacting trial timelines.
What Are EDC Systems?
An Electronic Data Capture system is a web-based software platform that replaces this entire paper workflow with direct digital data entry. Instead of filling out paper forms, site staff enter data directly into electronic CRFs (eCRFs) through a secure online interface. The data is immediately available for review by sponsors, clinical monitors, and data management teams.
EDC systems incorporate automated edit checks that validate data at the point of entry — flagging out-of-range values, missing fields, and logical inconsistencies in real time. Queries are generated and resolved electronically within the platform, eliminating the delays inherent in paper-based DCF cycles. A comprehensive audit trail records every data entry, modification, and query resolution with timestamps and user identification.
Head-to-Head Comparison
Data Quality
Data quality is arguably the most critical factor in any clinical trial, and it is where EDC systems demonstrate their most significant advantage over paper.
Paper CRFs introduce multiple opportunities for error. Handwritten entries can be illegible — a frequent source of data queries, as documented by researchers at the Institute of Cancer Research Clinical Trials & Statistics Unit (ICR-CTSU) in their published comparison of EDC and paper-based processes. Transcription from paper to database during double data entry adds another layer of potential mistakes. A study published in the journal Drug Information that analyzed data changes in an EDC clinical trial database found that the main errors observed were simple transcription errors from paper source documents to the EDC system — errors that would not occur with direct electronic data entry.
EDC systems reduce these risks through built-in validation. Edit checks catch out-of-range values and logical inconsistencies immediately. Required fields prevent incomplete submissions. Standardized dropdown menus and date pickers eliminate formatting variations. While no system eliminates all errors, the automated safeguards in EDC platforms systematically address the most common sources of data quality problems in paper-based trials.
Cost
The cost difference between paper and EDC processes has been studied in peer-reviewed research. A simulation study published in Contemporary Clinical Trials modeled the complete data collection process for both methods using Extended Event-driven Process Chains. The researchers found that the EDC process decreased data collection costs by approximately 55%, with savings ranging from 49% to 62% depending on the scenario parameters.
A separate study conducted across 27 clinical trials at the Paris public hospital consortium (Assistance Publique – Hôpitaux de Paris) found that the total cost per patient was substantially lower with eCRFs — €374 on average compared to €1,135 with paper CRFs. The difference reflects the elimination of printing, shipping, physical storage, manual data entry, and double data entry verification that paper processes require.
For EDC, the primary costs are software licensing, system validation, study build, and user training. These costs are largely upfront and fixed, meaning the per-patient cost advantage of EDC grows as trial size increases. For large multinational Phase III trials with thousands of patients, the financial case for EDC is compelling.
However, for very small, single-site studies with simple protocols, the upfront investment in EDC licensing and validation can be proportionally higher. This is one reason why some smaller academic studies and medical device trials have been slower to adopt EDC, though modern cloud-based platforms with flexible pricing models are increasingly addressing this barrier.
Speed and Timeline
Clinical trial timelines directly impact how quickly new treatments reach patients and how efficiently sponsors deploy their development budgets. EDC systems provide significant time advantages at multiple stages of the trial lifecycle.
The Paris hospital study found that clinical studies using eCRFs were completed faster — 31.7 months on average versus 39.8 months for paper-based studies. While the difference in that particular dataset did not reach statistical significance (p = 0.11), the trend is consistent with the operational advantages EDC provides.
The speed advantage comes from several sources. With paper CRFs, data is not available for review until physical forms are transported to the data center and manually entered — a process that can take days to weeks per data batch. With EDC, data is available immediately upon entry. This real-time access allows clinical data management teams to begin data review and cleaning concurrently with data collection, rather than waiting for batch deliveries.
Query resolution is similarly accelerated. Paper-based queries travel via DCFs — printed, mailed, responded to on paper, and mailed back. This cycle can take weeks per round. In an EDC system, queries are generated, communicated, and resolved electronically within the same platform, often within days.
Database lock timelines — the critical milestone after which data becomes available for statistical analysis — are typically shorter with EDC because much of the data cleaning has been completed in real time throughout the trial, rather than compressed into a post-collection cleaning phase.
Regulatory Compliance
Both paper and EDC processes can meet regulatory requirements, but they do so through fundamentally different mechanisms.
Paper CRFs rely on physical controls: locked filing cabinets, restricted room access, and handwritten signatures with dates. While these methods have served the industry for decades, they have inherent limitations. Signatures can be illegible, making it difficult to confirm who signed a form. Physical security depends on consistent human behavior. And reconstructing a complete audit trail from paper records during a regulatory inspection is significantly more labor-intensive than retrieving one from an electronic system.
EDC systems are designed from the ground up to comply with FDA 21 CFR Part 11, which establishes the criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records. Compliant EDC platforms provide automated, tamper-evident audit trails and ALCOA principles built into the system architecture; role-based access controls with unique user identification; validated electronic signatures; system validation documentation; and encrypted data storage and transmission. Under ICH E6(R3), data integrity is further governed by the ALCOA++ principles (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available), which apply explicitly to both electronic and paper-based records. For a detailed walkthrough of what EDC validation involves in practice, see our guide to EDC validation requirements.
The FDA's finalized guidance from October 2024 on electronic systems in clinical investigations confirmed that Part 11 compliance will be assessed once electronic records enter a sponsor's EDC system. This guidance also clarified that sponsors bear ultimate responsibility for ensuring their EDC systems meet regulatory requirements — regardless of whether the system is hosted internally or by a third-party vendor.
For European trials, EU GMP Annex 11 imposes comparable requirements with additional emphasis on risk assessment and the complete system lifecycle. ICH E6(R3) Good Clinical Practice guidelines, finalised in January 2025 and effective from 23 July 2025, provide the overarching quality framework that applies to both paper and electronic data collection methods. E6(R3) explicitly supports the use of electronic records, remote monitoring, and digital health technologies — representing a significant update from the previous R2 version.
Remote Monitoring and Oversight
The ability to monitor trial data remotely has become increasingly important, and it represents an area where EDC systems offer capabilities that paper simply cannot match.
With paper CRFs, clinical research associates (CRAs) must physically visit each trial site to review source documents, verify data entries, and resolve queries. This site-centric monitoring model is expensive, time-consuming, and limited in frequency.
EDC systems enable centralized monitoring, where data management and medical monitoring teams can review data from all sites in real time without traveling. This supports risk-based monitoring (RBM) approaches, which are now formally embedded as a core principle within ICH E6(R3). Unlike E6(R2), which introduced RBM concepts as an addendum, E6(R3) treats proportionate, risk-based oversight as a foundational requirement — moving beyond the FDA and EMA endorsement to make it an explicit GCP standard. Statistical algorithms can identify data anomalies, enrollment patterns, and potential safety signals continuously across the entire trial population.
Scalability
Paper-based processes become exponentially more difficult to manage as trial size and geographic scope increase. Every additional site means more physical forms, more shipping logistics, more storage requirements, and more data entry capacity.
EDC systems scale more efficiently. Adding a new site primarily requires creating user accounts, deploying the study configuration, and providing training. The same platform serves ten sites or ten thousand sites, and data from a site in Mumbai is accessible at the same speed as data from a site in Boston. For multinational trials requiring multiple languages, EDC systems deploy translated eCRFs through the same platform while maintaining consistent data structures — a significant logistical advantage over printed multilingual paper forms.
When Paper CRFs Are Still Used
Despite the clear advantages of EDC, paper CRFs have not disappeared entirely. Some situations where paper remains in use include very small investigator-initiated studies with extremely limited budgets, certain regulatory environments in developing countries where digital infrastructure is not yet reliable, specific study types where handwritten patient diaries serve as source documents, and trials at sites without consistent internet connectivity.
However, the trend is unmistakably toward electronic data capture. The global EDC systems market was valued at approximately $1.88 billion in 2024 and is projected to reach $4.2 billion by 2032, reflecting a compound annual growth rate of over 10%. Modern cloud-based EDC platforms with flexible pricing, offline data entry capabilities, and intuitive interfaces are progressively addressing the barriers that historically kept some organizations on paper.
Making the Transition
For organizations still using paper CRFs, the transition to EDC requires thoughtful planning but offers substantial long-term returns. Key steps include evaluating EDC vendors based on trial needs and budget (our guide to top EDC vendors covers the current landscape), planning for system validation and regulatory compliance from the outset, investing in user training for both data management teams and site staff, and establishing clear data management plans that leverage EDC capabilities.
The selection process itself depends on whether you are choosing a system for a single study or for your company's broader clinical programme. Our guides to trial-level EDC selection and company-level EDC platform strategy cover both approaches in detail.
TriTiCon's clinical data management training programs cover the complete clinical technology landscape, including EDC system setup, eCRF design, edit check development, and the integration of EDC within the broader clinical data management process. Explore the TriTiCon course platform and free resources.
Frequently Asked Questions
Is paper still acceptable for clinical trials?
Yes, regulatory agencies do not mandate the use of EDC systems. Paper CRFs remain acceptable provided they meet Good Clinical Practice (GCP) requirements for data integrity, traceability, and security. However, the operational advantages of EDC make electronic data capture the preferred approach for the vast majority of modern clinical trials.
How quickly can a team transition from paper to EDC?
For a straightforward single-study implementation, the process — including vendor selection, system validation, study build, and user training — typically takes two to four months. Organization-wide adoption across multiple studies may take six to twelve months.
Does EDC eliminate all data errors?
No. EDC systems significantly reduce transcription errors, illegibility issues, and formatting inconsistencies, but data entry mistakes at the source and clinical judgment errors can still occur. EDC reduces errors at the technology layer; comprehensive training and quality processes address the human layer.
This article is part of TriTiCon's USA Technology content series on clinical data management. For a comprehensive overview of EDC platforms and technology, see our Complete Guide to EDC Systems in Clinical Trials (2026).
Related articles:
- Complete Guide to EDC Systems in Clinical Trials 2026
- Top EDC Vendors 2026: Choosing the Right Platform
- EDC System Selection Guide: Trial-by-Trial Approach
- EDC System Selection Guide: Company-Level Platform Strategy
- EDC Validation Requirements: Meeting FDA 21 CFR Part 11
- EDC User Training Best Practices for Clinical Trial Sites
